Sarcoma Treatment Guide in Improving Self-Monitoring in Patients With Sarcoma Receiving Chemotherapy
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 50
Summary
- Conditions
- Sarcoma
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: RandomizedIntervention Model: Crossover AssignmentMasking: None (Open Label)Primary Purpose: Supportive Care
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
PRIMARY OBJECTIVES: I. To evaluate whether symptom management and communication are improved in patients who are chemotherapy naive who receive a Sarcoma Treatment Guide as compared to those that have not. SECONDARY OBJECTIVES: I. To explore whether patients who have previously undergone chemotherap...
PRIMARY OBJECTIVES: I. To evaluate whether symptom management and communication are improved in patients who are chemotherapy naive who receive a Sarcoma Treatment Guide as compared to those that have not. SECONDARY OBJECTIVES: I. To explore whether patients who have previously undergone chemotherapy benefit from a Sarcoma Treatment Guide (STG) in regard to symptom management and have improved communication between patient and providers. II. To assess patient satisfaction with using the STG at the end of the trial. OUTLINE: Patients are randomized to 1 of 2 arms. ARM A: Patients receive the STG before completing 4 courses of standard of care chemotherapy. ARM B: Patients complete 2 courses of standard of care chemotherapy and then receive the STG before completing 2 additional courses of standard of care chemotherapy.
Tracking Information
- NCT #
- NCT03258892
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: James Chen, MD Ohio State University Comprehensive Cancer Center